Table 4.
EUD of CTV_AxI, CTV_AxII, and CTV_AxIII in nominal PB‐PB, PB‐MC, and MC‐MC plans of breast cancer.
| Patient # | CTV_AxI | CTV_AxII | CTV_AxIII | ||||||
|---|---|---|---|---|---|---|---|---|---|
| EUD (Gy(RBE) | EUD (Gy(RBE) | EUD (Gy(RBE) | |||||||
| PB‐PB | PB‐MC | MC‐MC | PB‐PB | PB‐MC | MC‐MC | PB‐PB | PB‐MC | MC‐MC | |
| 1 | 51.7 | 49.6 | 51.7 | 51.6 | 50.4 | 51.6 | 50.9 | 50.0 | 50.9 |
| 2 | 51.8 | 49.9 | 51.4 | 51.7 | 49.8 | 51.3 | 51.4 | 50.0 | 51.1 |
| 3 | 50.6 | 48.2 | 50.5 | 50.6 | 48.8 | 50.5 | 50.6 | 49.1 | 50.5 |
| 4 | 50.5 | 48.9 | 49.5 | 50.5 | 49.3 | 49.5 | 49.9 | 47.3 | 49.7 |
| 5 | 51.6 | 49.2 | 51.4 | 51.8 | 50.3 | 51.7 | 51.3 | 49.5 | 50.8 |
| 6 | 49.9 | 47.7 | 49.8 | 49.8 | 47.4 | 49.8 | 49.9 | 47.3 | 49.7 |
| 7 | 50.8 | 47.1 | 50.9 | 50.8 | 48.6 | 50.8 | 50.8 | 48.6 | 50.8 |
| 8 | 51.2 | 49.0 | 50.3 | 51.2 | 49.4 | 50.3 | 51.2 | 49.6 | 50.2 |
| 9 | 51.0 | 49.2 | 50.2 | 50.9 | 49.2 | 50.0 | 50.8 | 49.2 | 49.8 |
| 10 | 50.8 | 48.6 | 50.8 | 50.7 | 48.8 | 50.7 | 50.7 | 48.6 | 50.7 |
| Average | 51.0 | 48.7 | 50.7 | 51.0 | 49.2 | 50.6 | 50.7 | 48.9 | 50.4 |
| SD | 0.6 | 0.9 | 0.7 | 0.6 | 0.9 | 0.7 | 0.5 | 1.0 | 0.5 |
| P‐value | <0.001 | 0.271 | <0.001 | 0.272 | 0.001 | 0.162 | |||
PB‐PB, PB optimization followed by PB dose calculation; PB‐MC, PB optimization followed by MC dose calculation; MC‐MC, MC optimization followed by MC dose calculation; CTV, clinical target volume, EUD, equivalent uniform dose; RBE, relative biological effectiveness.
P‐value for PB‐MC vs. PB‐PB.
P‐value for MC‐MC vs. PB‐PB.